Abstract:Objective: To investigate the relationship between early-stage renal acute rejection(AR) and the level of Fractalkine in urine, explore the diagnostic and noninvasive monitoring value in early stage after transplantation by measurement of urine Fractalkine. Methods: Urine samples were examined from renal transplant patients between January 2006 and October 2009. A total of 155 patients were enrolled, including 49 with biopsy-proved AR, 58 patients with stable renal function and no abnormal histological findings, 10 patients with subclinical rejection in protocol biopsy, 9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urine samples were also collected from 40 healthy controls. Fractalkine was measured in urine samples using a commercial human Fractalkine enzyme-linked immunosorbent assay (ELISA) kit. Immunohistochemistry for Fractalkine expression was performed on biopsies from renal transplant patients with AR and non-AR. Results: Forty-nine patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with stable renal function and healthy controls[(429.1±56.1)vs (94.6±8.4), (84.5±8.9)ng/mmol creatine, both P<0.001]. Patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with acute tubular necrosis and chronic allograft nephropathy[(429.1±56.1)vs(133.0±9.8), (183.0±18.9)ng/mmol creatine, both P<0.001]. Receiver operating characteristic(ROC)curve was constructed to determine the discriminatory power of Fractalkine levels for diagnosis of AR. The area under ROC curve was 0.920(95% CI: 0.875-0.969, P<0.001), which showed that Fractalkine was a suitable marker for the diagnosis of AR. At a cut-off point of 157.5 ng/mmol creatinine, the sensitivity was 83.7% and the specificity was 84.5% (P<0.001). The dynamic level of urinary Fractalkine in AR patients within 3 weeks after transplantation fluctuated above 300 ng/mmol creatine, which is remarkably higher than patients with stable renal function (below 200 ng/mmol creatinine). Conclusions: As a noninvasive monitoring method, Fractalkine in urine may be a new approach for detection of AR as well as useful to predict response to antirejection therapy. It has good sensitivity and specificity. Besides, measurement of Fractalkine in urine is a simple, inexpensive method for the routine clinical monitoring after kidney transplantation.

Prediction of Subclinical Renal Allograft Rejection by Vascular Endothelial Growth Factor in Serum and Urine.

Non-invasive detection of acute renal allograft rejection by measurement of vascular endothelial growth factor in urine.

Acute Renal Allograft Rejection is Associated with Increased Levels of Vascular Endothelial Growth Factor in the Urine

Biomarkers for Renal Transplantation: Where Are We?

Urinary C-X-C Motif Chemokines 13 is a Noninvasive Biomarker of Antibody-Mediated Renal Allograft Rejection

[Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients with Acute Rejection by Measurement of Urine Fractalkine].

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Artificial Urinary Biomarkers for Early Diagnosis of Acute Renal Allograft Rejection

Serum Fractalkine and Interferon-Gamma Inducible Protein-10 Concentrations Are Early Detection Markers for Acute Renal Allograft Rejection

Association of Pre-Transplant Serum Level of Anti-Endothelial Cell Antibody with Acute Rejection in Kidney Transplant Recipients

Extracellular vesicles as potential diagnostic markers for kidney allograft rejection

Kidney transplant monitoring by urinary flow cytometry: Biomarker combination of T cells, renal tubular epithelial cells, and podocalyxin-positive cells detects rejection

Diagnosis of Renal Allograft Subclinical Rejection by Urine Protein Fingerprint Analysis.

Quantitative ultrasound for non-invasive evaluation of subclinical rejection in renal transplantation

[Clinical Significance of Early Diagnose and Treatment of Subclinical Renal Allograft Rejection].

Developing Renal Allograft Surveillance Strategies – Urinary Biomarkers of Cellular Rejection

Non-Invasive Diagnosis for Acute Rejection Using Urinary mRNA Signature Reflecting Allograft Status in Kidney Transplantation

A Novel Accurate Rapid ELISA for Detection of Urinary Connective Tissue Growth Factor, a Biomarker of Chronic Allograft Nephropathy.

Identification of a Novel Peripheral Blood Signature Diagnosing Subclinical Acute Rejection after Renal Transplantation

Prediction of Acute Renal Allograft Rejection by Combined HLA-G 14-Bp Insertion/deletion Genotype Analysis and Detection of Kidney Injury Molecule-1 and Osteopontin in the Peripheral Blood.